Takeda revises FY2025 results after AMITIZA® antitrust verdict

Revised FY2025 reported results

Takeda filed a revised Earnings Report to reflect the impact of a U.S. jury verdict in the AMITIZA® (lubiprostone) antitrust litigation on its consolidated financial statements for fiscal year 2025 (ended March 31, 2026). The company recorded an additional provision for legal proceedings of JPY 402.5 billion and recognized related tax benefits of JPY 58.4 billion in the FY2025 consolidated statements.

Guidance and dividends

Takeda states the revision does not affect its Core financial results for FY2025 and does not change the FY2026 financial forecast or Management Guidance, including the forecast for adjusted free cash flow. The year‑end dividend for FY2025 remains JPY 100 per share and the annual dividend forecast for FY2026 remains JPY 204 per share.

Legal proceedings and next steps

The company will vigorously pursue post‑trial motions and an appeal, seek a stay of execution of the judgment during the appeal, and continue to assess potential financial impacts. Takeda expects a district court judgment through the second half of calendar year 2026 and will provide updates as necessary.

Management comment and pipeline

CFO Milano Furuta said the company will appeal and that the matter does not change its business momentum or FY2026 guidance. He noted Takeda has three major launches planned in the next 12 months and a pipeline of five additional late‑stage assets. Revised financial materials are available on Takeda’s Quarterly Results page.